Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Screening Cancer Patients for Lynch Syndrome Extends Lives

By LabMedica International staff writers
Posted on 28 Jul 2011
Screening every new colon cancer patient for a familial disorder called Lynch syndrome extends lives at a reasonable cost.

Lynch syndrome is caused by mutations in a set of genes that normally run quality control on the DNA of cells. More...
The loss of such a molecular DNA inspector predisposes Lynch syndrome patients to tumor growth. Unusual patterns in the DNA of tumor cells or a missing inspector indicate that there is diminished quality control. As soon as a pathologist identifies a tumor that might be caused by the disorder, more tests are needed to determine if the patient carries a particular mutation.

The most cost-effective method involved checking whether tumors were missing any molecular quality inspectors, followed by DNA sequencing of the suspected gene.

Approximately 3% to 5% of colorectal tumors are caused by Lynch syndrome, which greatly increases the odds of colon and other cancers in a person's lifetime. Siblings and children of someone with Lynch syndrome each have a 50% chance of carrying the mutation, so the first diagnosis in a family reveals the risk for many relatives.

"This is a situation where, if you find out genetic information, you can improve your outcome," said Uri Ladabaum, MD, associate professor of gastroenterology and hepatology at the Stanford University School of Medicine (Stanford, CA, USA) and lead author of the study. Lynch syndrome patients can take defensive steps (such as yearly colonoscopies) that can either prevent cancer or alert them to get cancer treatment early, when it has the best chance of working.

Prof. Ladabaum and colleagues used computer simulations to compare the years of lives gained and the money spent if all new cases of colorectal cancer were tested for Lynch syndrome. They found that such screening programs could reduce cancer deaths at a price within the typical range of US healthcare costs. The study was published in the July 19, 2011, issue of Annals of Internal Medicine.

Prior to the availability of genetic testing, Lynch syndrome was identified by observant genetic counselors and physicians who noticed the high frequency of cancers in certain families. However, this method is not foolproof, especially if a patient does not know his or her family history. If Lynch syndrome is present a person's lifetime risk of developing colon cancer increases from 5% to 70%.

The study suggests that more medical centers could adopt tumor-screening policies like Stanford's. "A systematic approach to identify families with Lynch syndrome makes sense clinically, because it can save lives, and economically, because its costs are comparable to other things we choose to spend our healthcare dollars on," said Prof. Ladabaum. "We advocate establishing similar tumor-screening systems on a national level."

Related Links:
Stanford University School of Medicine




New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.